Blog
RSS FeedPosted by Michael Wonder on 29 May 2023
MSAC publishes agenda for August PASC meeting
29 May 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the PICO ...
Posted by Michael Wonder on 24 May 2023
PBAC Public Summary Document - May 2023
24 May 2023 - The Public Summary Document of the PBAC's consideration of the interim report of the post-market review of ...
Posted by Michael Wonder on 22 May 2023
EMA publishes agenda for 22-25 May 2023 CHMP meeting
22 May 2023 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 17 May 2023
Publication of EMA Annual Report 2022
15 May 2023 - EMA published its annual report 2022 today. ...
Posted by Michael Wonder on 05 May 2023
Updated agenda for the July 2023 PBAC meeting
5 May 2023 - The agenda for the July 2023 PBAC meeting has been updated. ...
Posted by Michael Wonder on 28 Apr 2023
Agenda for the May 2023 intracycle meeting
28 April 2023 - The agenda for the May 2023 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 18 Apr 2023
Cost effectiveness thresholds used by study authors (1990-2021)
18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...
Posted by Michael Wonder on 17 Apr 2023
ICER publishes final evidence report on lecanemab for Alzheimer’s disease
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 06 Apr 2023
Public summary documents – December 2022 PBAC meeting
6 April 2023 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2022 PBAC ...
Posted by Michael Wonder on 29 Mar 2023
MSAC Secretariat publishes agenda for July 2023 MSAC meeting
29 March 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC ...
Posted by Michael Wonder on 29 Mar 2023
Agenda for the July 2023 PBAC meeting
29 March 2023 - The agenda for the July 2023 PBAC meeting is now available. ...
Posted by Michael Wonder on 27 Mar 2023
FDA outlines plan for digital health technologies for clinical trials
24 March 2023 - The US FDA plans to hold at least one public meeting and release several guidances on digital ...